Gemcitabine, used to treat breast cancer recurrence, induces the release of characteristic immunostimulatory DAMPs, such as HMGB1, CRT, and HSP70, in bladder cancer cells, but does not cause ICD of these cells [105]. This evidence concerns the gene CALR and breast carcinoma.